Fluidigm Logo
STORE
Fluidigm Logo
STORE
Area of Interest COVID-19

COVID-19 Vaccine Development

background pattern

Simple. Powerful. Fast.
Immune System Monitoring with CyTOF

You need answers from every cell in each precious patient sample, and you need them quickly, reliably.

Mass cytometry, powered by CyTOF® technology, can expedite COVID-19 therapeutic and vaccine research studies with best-in-class, highly multiplexed, longitudinal immune monitoring capability.

Faster and more cost-efficient than single-cell RNA-seq, CITE-seq or AbSeq, mass cytometry also provides deeper resolution of immune cell phenotype and function than any flow cytometry or spectral cytometry system.

And CyTOF does it all in a single tube.

Get the flyer

Webinar: Uncovering Immunological Mechanisms of Protection from Infection and Vaccination in Humans

In this presentation, Marcelo B. Sztein, MD, shows examples of his group’s use of mass cytometry to help advance the fields of vaccine development and pathogen-host interactions. He provides an in-depth look at his studies of Salmonella typhi (S. typhi), the causative agent of typhoid fever, an infectious disease of great public health importance.

Register to watch

Presenter:

Marcelo B. Sztein, MD
Center for Vaccine Development and Global Health
University of Maryland

 

Jump-start your SARS-CoV-2 vaccine and COVID-19 therapeutic research with the Maxpar Direct Immune Profiling System.

Contact us

 

Best-in-class longitudinal immune profiling

Solves multi-site study challenges

Panel flexibility and expansion

We chose the Maxpar Direct Immune Profiling Assay for this study* because it provides a robust and standardized solution for comprehensive immune monitoring that is technically easy to execute and harmonize across multiple study sites. ”

– Adeeb Rahman, PhD | Icahn School of Medicine at Mount Sinai

* Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC)

Related Webinars

Seminar: A Complete Immune Monitoring Solution with CyTOF; Ideal for Pandemics and Beyond

Frederik De Smet, MSc, PhD, presents early data from the COVID-19 Advanced Genetic and Immunologic Sampling (COntAGIouS) clinical research study (NCT04327570) using the Maxpar® Direct™ Immune Profiling Assay™ and Maxpar Pathsetter™ software.

Watch now

Presenter:

Professor Frederik De Smet, MSc, PhD
Assistant Professor
University of Leuven, Belgium

Webinar: Profiling of COVID-19 Patient Immune Responses


Ruth Montgomery, PhD, describes her team’s work using mass cytometry in infectious disease studies and how her team will contribute to the IMPACC study by analyzing endotracheal aspirates from participants.

Watch now

Presenter:

Ruth Montgomery, PhD
Professor of Internal Medicine
Director, Yale CyTOF Facility
Associate Dean for Scientific Affairs

Published research and trials using the Maxpar Direct Immune Profiling Assay

Summary

Summary of COVID-19 trials and publications using CyTOF

Publications

Hadjadj, J. et al. “Impaired type I interferon activity and exacerbated inflammatory responses in severe COVID-19 patients.” Science (2020): 718–724.
Ausar, S.F. et al. “Genetically detoxified pertussis toxin displays near identical structure to its wild-type and exhibits robust immunogenicity.” Communications Biology 3 (2020): 427.
Zheng, Y. et al. “A human circulating immune cell landscape in aging and COVID-19.” Protein & Cell (2020): 740–770.
Geanon, D. et al. “A streamlined CyTOF workflow to facilitate standardized multi-site immune profiling of COVID-19 patients.” medRxiv (2020): doi:10.1101/2020.06.26.20141341.

Publications Overviews

January 2022 COVID-19 Research Updates
July 2020 COVID-19 Disease Research

National Clinical Trials

Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) (NCT04378777) | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); 10 participating institutions in North America
In-Depth Immunological Investigation of COVID-19. (COntAGIouS) (NCT04327570) | Sponsor: Universitaire Ziekenhuizen Leuven
Antidepressant Trial with P2X7 Antagonist JNJ-54175446 (ATP) (NCT04116606) | Sponsor: CCTU-Core

Clinical trials using mass cytometry in vaccine research as of September 30, 2020. 

Clinical Trial Name

Sponsor

Start Date

Phase

NCT Number
FluPRINT Study: Characterisation of the Immune and Transcriptional Response to LAIV University of Oxford October 2019 NA* 04222595
CVD 38000: Study of Responses to Vaccination with Typhoid and/or Cholera University of Maryland November 2018 4 03705585
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant Vanderbilt-Ingram Cancer Center/ National Cancer Institute September 2016 2 02860039
Investigating Enteric Fever—Salmonella Typhi and Paratyphi Challenge Study University of Oxford, Oxford Vaccine Group December 2014 NA* 02192008
Genetic and Environmental Factors in the Response to Influenza Vaccination (SLVP028) Stanford University October 2014 1 03088904
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection (SLVP030) Stanford University September 2014 1 03453801
CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults University of Maryland October 2013 4 03970304
Study of a New MVA Vaccine for Hepatitis C Virus ReiThera Srl December 2010 1 01296451
Blood Donor CVD 5000 University of Maryland January 2004 4 03971669

Table 1. Clinical trials using mass cytometry to study vaccine response as of September 30, 2020. Source: clinicaltrials.gov * NA=Not applicable 

Key Publications Applying Mass Cytometry for Vaccine Research

Publications

Brodin, P. “Technologies for assessing vaccine responses in the very young.” Current Opinion in Immunology 65 (2020):28–31.
Chng, M.H.Y. et al. “Large-scale HLA tetramer tracking of T cells during dengue infection reveals broad acute activation and differentiation into two memory cell fates.” Immunity 51 (2019): 1,119–1,135.
Lingblom, C.M.D. et al. “Baseline immune profile by CyTOF® can predict response to an investigational adjuvanted vaccine in elderly adults.” Journal of Translational Medicine 16 (2018): 153.
Lucchesi, S. et al. “From bivariate to multivariate analysis of cytometric data: overview of computational methods and their application in vaccination studies.” Vaccines 8 (2020): 138.
Newell E.W. et al. “Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization.” Nature Biotechnology 31 (2013): 623–629.
Palgen, J-L. et al. “Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations.” npj Vaccines (2020): 24.
Palgen, J-L. et al. “NK cell immune responses differ after prime and boost vaccination.” Journal of Leukocyte Biology 105 (2019) : 1,055–1,073
Palgen, J-L. et al. “Prime and boost vaccination elicit a distinct innate myeloid cell immune response.” Scientific Reports 8 (2018): 3,087.
Reeves, P.M. et al. “Application and utility of mass cytometry in vaccine development.” FASEB Journal 32: (2018): 5–15.
Rudolph, M.E. et al. “Diversity of Salmonella Typhi-responsive CD4 and CD8 T cells before and after Ty21a typhoid vaccination in children and adults.” International Immunology 31 (2019): 315–333.
Tomic, A. et al. “SIMON, an automated machine learning system, reveals immune signatures of influenza vaccine responses.” The Journal of Immunology 203 (2019): 749–759.
Tomic, A. et al. “The FluPRINT dataset, a multidimensional analysis of the influenza vaccine imprint on the immune system.” Scientific Data 6 (2019): 214.

Get more information

For Research Use Only. Not for use in diagnostic procedures. Patent and License Information: www.standardbio.com/legal/notices. Trademarks: www.standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. All rights reserved.